Salute e Benessere
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025.
Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET.
To participate in the conference call or to watch the live webcast, please register in advance using the links below.
Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.
The webcast will also be accessible on the Pharming website at Investors/Financial Documents, and a replay will be available shortly after the event.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti